SCHEMBL1965000

SCHEMBL1965000

CNC(=O)C1CCCCN1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRCP P42785 3/20 0.47
DPP7 Q9UHL4 1/20 0.42
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
ULK1 O75385 1/20 0.40
MMP9 P14780 2/20 0.39
ADAM17 P78536 1/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
NOS2 P35228 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
CTSC P53634 2/20 0.37
CTSK P43235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22221409 1.00 PRCP (0.47) PRCPDPP7HTR2CHTR2BCYP3A4
SCHEMBL13306379 1.00 PRCP (0.47) PRCPDPP7HTR2CHTR2BCYP3A4
SCHEMBL29789556 0.98 PRCP (0.46) PRCPDPP7HTR2CHTR2BCYP3A4
Hydrochloric Acid SCHEMBL29755265 0.98 PRCP (0.46) PRCPDPP7HTR2CHTR2BCYP3A4
Hydrochloric Acid SCHEMBL3266641 0.98 PRCP (0.46) PRCPDPP7HTR2CHTR2BCYP3A4
SCHEMBL1174593 0.94
SCHEMBL1174591 0.94
SCHEMBL5616351 0.94
Hydrochloric Acid SCHEMBL1465143 0.92 PRCP (0.51) PRCPDPP7HTR2CHTR2BNOS2
Hydrochloric Acid SCHEMBL530196 0.92 PRCP (0.51) PRCPDPP7HTR2CHTR2BNOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013755-B1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2025-01-08 EP claimed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 US claimed
US-20180258092-A9 Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-09-13 US claimed
US-20180057497-A1 Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2018-03-01 US claimed
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP claimed
EP-1696822-B1 INJECTABLE SUSTAINED RELEASE IMPLANT HAVING A BIOERODIBLE MATRIX CORE AND A BIOERODIBLE SKIN PSIVIDA INC (US) 2010-03-17 EP claimed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US claimed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US claimed
EP-1856095-A1 QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS AstraZeneca AB (SE) 2007-11-21 EP claimed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP claimed
EP-1079819-A1 HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-03-07 EP claimed
EP-1052984-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-11-22 EP claimed
US-6022873-A Metalloproteinase inhibitors BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-02-08 US claimed
WO-1999059568-A1 HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-11-25 WO claimed
EP-0944597-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-09-29 EP claimed
WO-1999039704-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-12 WO claimed
EP-0934292-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-11 EP claimed
WO-1998023588-A9 METALLOPROTEINASE INHIBITORS 1998-09-17 WO claimed
WO-1998023588-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-06-04 WO claimed
WO-1998017655-A1 METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-04-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 PRCP 3550/4885DPP7 2213/4885HTR2C 221/4885
US-20180057497-A1 Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors CDK15, CDK1, CDK19 PRCP 3012/4885DPP7 1746/4885HTR2C 2592/4885
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 PRCP 3508/4885DPP7 3012/4885HTR2C 2297/4885
US-20180258092-A9 Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors CDK15, CDK1, CDK19 PRCP 3012/4885DPP7 1746/4885HTR2C 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.